RGEN Repligen Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN

Price (delayed)

$167.05

Market cap

$9.28B

P/E Ratio

49.87

Dividend/share

N/A

EPS

$3.35

Enterprise value

$9.18B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
The stock's P/E is 60% below its 5-year quarterly average of 125.1 and 17% below its last 4 quarters average of 60.1
The company's net income rose by 45% YoY and by 12% QoQ
RGEN's quick ratio is up by 9% since the previous quarter but it is down by 4.7% year-on-year
The debt has grown by 16% YoY
RGEN's gross margin is down by 2.4% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.repligen.com/
Peers: NVAX BMRN NBIX GE

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
55.56M
Market cap
$9.28B
Enterprise value
$9.18B
Valuations
Price to earnings (P/E)
49.87
Price to book (P/B)
4.85
Price to sales (P/S)
11.56
EV/EBIT
41.68
EV/EBITDA
33.84
EV/Sales
11.45
Earnings
Revenue
$801.54M
EBIT
$220.3M
EBITDA
$271.29M
Free cash flow
$38.74M
Per share
EPS
$3.35
Free cash flow per share
$0.7
Book value per share
$34.41
Revenue per share
$14.45
TBVPS
$23.72
Balance sheet
Total assets
$2.52B
Total liabilities
$613.96M
Debt
$422.96M
Equity
$1.91B
Working capital
$593.92M
Liquidity
Debt to equity
0.22
Current ratio
2.47
Quick ratio
1.83
Net debt/EBITDA
-0.37
Margins
EBITDA margin
33.8%
Gross margin
56.9%
Net margin
23.2%
Operating margin
28%
Efficiency
Return on assets
7.6%
Return on equity
10.2%
Return on invested capital
32.2%
Return on capital employed
10.4%
Return on sales
27.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
4.24%
1 week
-3.06%
1 month
-3.6%
1 year
-7.48%
YTD
-1.33%
QTD
-1.33%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$801.54M
Gross profit
$455.71M
Operating income
$224.67M
Net income
$185.96M
Gross margin
56.9%
Net margin
23.2%
The company's net income rose by 45% YoY and by 12% QoQ
The operating income has increased by 34% YoY and by 5% from the previous quarter
The net margin has grown by 21% YoY and by 12% from the previous quarter
The revenue has grown by 20% YoY

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
49.87
P/B
4.85
P/S
11.56
EV/EBIT
41.68
EV/EBITDA
33.84
EV/Sales
11.45
The stock's P/E is 60% below its 5-year quarterly average of 125.1 and 17% below its last 4 quarters average of 60.1
RGEN's EPS is up by 44% year-on-year and by 12% since the previous quarter
The P/B is 10% less than the 5-year quarterly average of 5.4 and 10% less than the last 4 quarters average of 5.4
Repligen's equity has increased by 9% YoY and by 4.1% QoQ
RGEN's P/S is 33% below its 5-year quarterly average of 17.2 and 8% below its last 4 quarters average of 12.6
The revenue has grown by 20% YoY

Efficiency

How efficient is Repligen business performance
The return on equity rose by 32% year-on-year and by 10% since the previous quarter
RGEN's ROA is up by 27% year-on-year and by 10% since the previous quarter
The ROIC has contracted by 22% YoY and by 2.7% from the previous quarter
RGEN's return on sales is up by 12% year-on-year and by 7% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio is up by 9% since the previous quarter but it is down by 4.7% year-on-year
Repligen's total assets has increased by 7% YoY and by 2.5% QoQ
The debt is 78% less than the equity
The debt has grown by 16% YoY
Repligen's equity has increased by 9% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.